Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug941 | Clofazimine Wiki | 0.71 |
drug4740 | some risk factors that might be correlated with TMD Wiki | 0.71 |
drug878 | ChAdOx1 MERS Wiki | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
D002012 | Bruxism NIH | 0.71 |
D007592 | Joint Diseases NIH | 0.50 |
D013705 | Temporomandibular Joint Disorders NIH | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0003763 | Bruxism HPO | 0.71 |
HP:0001367 | Abnormal joint morphology HPO | 0.50 |
Navigate: Correlations HPO
There are 2 clinical trials
To conduct an open-label randomized controlled trial on a short course of interferon β-1b and clofazimine combination treatment for patients hospitalized for COVID-19 infection. To assess its safety and clinical efficacy.
Description: Time to complete alleviation of symptoms as defined by NEWS of 0 maintained for 24 hours
Measure: Clinical alleviation of symptoms Time: 7 daysDescription: Length of hospitalisation
Measure: Hospitalisation Time: 14 daysDescription: Time to negative nasopharyngeal swab, throat saliva and sputum viral load by RT-PCR
Measure: Time to negative viral load Time: 7 daysDescription: Cytokine/ chemokine changes
Measure: Inflammatory changes Time: 7 daysDescription: One month mortality rate
Measure: Mortality Time: 30 daysDescription: Adverse events during and shortly after treatment
Measure: Adverse events Time: 30 daysAs of 1 July 2020, more than 10 million people been confirmed to have infected by SARS-CoV-2, resulting in more than 500,000 deaths. No specific antiviral treatment for the SARS-CoV-2 is currently available, but existing medication could be repurposed. The investigators therefore propose to conduct an open-label randomized controlled trial on a short course of interferon β-1b and ribavirin combination treatment for patients hospitalized for COVID-19 infection.
Description: Time to complete alleviation of symptoms as defined by NEWS2 of 0 maintained for 24 hours
Measure: Clinical symptoms alleviation Time: 7 daysDescription: Length of hospitalisation
Measure: Hospitalisation Time: 14 daysDescription: Time to negative nasopharyngeal swab and throat saliva viral load by RT-PCR
Measure: Time to negative viral load Time: 7 daysDescription: Cytokine/ chemokine changes
Measure: Inflammatory changes Time: 7 daysDescription: One month mortality rate
Measure: Mortality Time: 30 daysDescription: Adverse events and serious adverse events within 30 days of treatment
Measure: Adverse events and serious adverse events Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports